A carregar...
Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
The efficacy and side effects of the second‐time humanized CD19 chimeric antigen receptor (CD19‐CAR) T‐cell therapy after unsuccessful first‐time anti‐CD19‐CAR T‐cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B‐cell lymphoma. In our study, 3 patient...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8253282/ https://ncbi.nlm.nih.gov/pubmed/33932067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14915 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|